JCI insightAnimalsDiabetes MellitusType 1MiceInbred NOD
Anti-CD3 mAb treatment reshapes infiltrating T and β cells in the islets in autoimmune diabetes.
Ying Wu, Maxwell Spurrell, Ana Lledó-Delgado, Songyan Deng, Dejiang Wang, Yang Liu, Mahsa Nouri Barkestani, Ana Luisa Perdigoto, Kevan C Herold
Published: 202610.1172/jci.insight.192755
Abstract
Treatment with anti-CD3 monoclonal antibody (mAb) can delay or prevent type 1 diabetes in mice and humans by modulating the immune-mediated destruction of β cells. A single course of treatment may have lasting efficacy, but the mechanisms that accoun…
Preview only. Read the full abstract at the source